Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.
Company profile
Ticker
PRME
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PRME stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
1 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
FWP
Free writing prospectus
14 Feb 24
Latest ownership filings
4
Jeffrey D Marrazzo
4 Mar 24
3
Initial statement of insider ownership
29 Feb 24
SC 13G/A
GV 2019, L.P.
29 Feb 24
4
Keith Michael Gottesdiener
27 Feb 24
4
Richard Brudnick
23 Feb 24
4
Jeremy Duffield
23 Feb 24
4
ANN L. LEE
23 Feb 24
4
Meredith Goldwasser
23 Feb 24
4
Carman Alenson
23 Feb 24
SC 13D
ARCH Venture Fund XII, L.P.
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.46 mm | 57.46 mm | 57.46 mm | 57.46 mm | 57.46 mm | 57.46 mm |
Cash burn (monthly) | 25.54 mm | 332.33 k | 17.15 mm | 14.62 mm | (no burn) | 3.19 mm |
Cash used (since last report) | 179.18 mm | 2.33 mm | 120.34 mm | 102.57 mm | n/a | 22.41 mm |
Cash remaining | -121.72 mm | 55.12 mm | -62.89 mm | -45.11 mm | n/a | 35.04 mm |
Runway (months of cash) | -4.8 | 165.9 | -3.7 | -3.1 | n/a | 11.0 |
Institutional ownership, Q3 2023
67.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 12 |
Closed positions | 7 |
Increased positions | 34 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 467.24 bn |
Total shares | 80.36 mm |
Total puts | 1.00 k |
Total calls | 10.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
GV 2019 | 13.28 mm | $0.00 |
ARCH Venture Fund X | 12.26 mm | $0.00 |
GOOGL Alphabet Inc - Ordinary Shares | 11.86 mm | $113.17 bn |
Newpath Partners | 5.31 mm | $0.00 |
Vanguard | 3.95 mm | $37.70 bn |
FMR | 3.92 mm | $37.42 bn |
CMTDF Sumitomo Mitsui Trust | 3.63 mm | $34.68 bn |
Nikko Asset Management Americas | 3.63 mm | $34.57 bn |
BLK Blackrock | 3.33 mm | $31.81 bn |
ARK Investment Management | 2.62 mm | $25.02 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Jeffrey D Marrazzo | Stock Option Common Stock | Grant | Acquire A | No | No | 8.63 | 250,000 | 2.16 mm | 250,000 |
25 Feb 24 | Gottesdiener Keith Michael | Stock Option Common Stock | Grant | Acquire A | No | No | 8.32 | 100,000 | 832.00 k | 100,000 |
17 Jan 24 | Allan Reine | Stock Option Common Stock | Grant | Acquire A | No | No | 6.8 | 600,000 | 4.08 mm | 600,000 |
News
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Apr 24
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
29 Apr 24
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
29 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
26 Apr 24
Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target
23 Apr 24
Press releases
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
29 Apr 24
Thinking about buying stock in KULR Technology, Prime Medicine, Solidion Technology, Sharp Corp, or Fisker?
15 Mar 24
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
20 Feb 24
Prime Medicine Announces Pricing of Upsized Public Offering
14 Feb 24
Prime Medicine Announces Proposed Public Offering of Common Stock
14 Feb 24